Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings cut Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.00.
View Our Latest Stock Report on Rocket One Inc. Common Stock
Rocket One Inc. Common Stock Price Performance
Rocket One Inc. Common Stock stock opened at $0.51 on Friday. The business has a 50 day moving average price of $0.71 and a two-hundred day moving average price of $0.83. Rocket One Inc. Common Stock has a 12 month low of $0.49 and a 12 month high of $2.45. The stock has a market cap of $11.32 million, a price-to-earnings ratio of -0.62 and a beta of 0.90.
Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.19) earnings per share for the quarter.
Hedge Funds Weigh In On Rocket One Inc. Common Stock
An institutional investor recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC increased its stake in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO – Free Report) by 100.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,000 shares of the company’s stock after buying an additional 19,500 shares during the quarter. Lido Advisors LLC owned 0.20% of Rocket One Inc. Common Stock worth $33,000 at the end of the most recent reporting period. 7.08% of the stock is currently owned by institutional investors and hedge funds.
Rocket One Inc. Common Stock Company Profile
Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
Further Reading
- Five stocks we like better than Rocket One Inc. Common Stock
- These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
- Meta Claims Frontier-Class AI Status With New Muse Wonder Models
- Berkshire Just Backed This Little-Known Stock—Should You Chase It?
- Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Rocket One Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket One Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
